Heliospect Genomics, a US startup, offers wealthy couples the option to screen embryos for traits like IQ, height, and mental illness, raising ethical concerns about genetic enhancement. Using polygenic scoring, the company charges up to $50,000 for embryo selection. Experts worry about social inequality and the moral implications of such controversial technology.